Northwire Canada EditionFriday, October 16, 2026
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8%
M&A / Property

WELL Health Partners with AliveCor to Bring AI-Powered Cardiac Monitoring and Cardiologist Oversight to Canadians

WELL · Price

Executive Summary

  • WELL Health Technologies Corp. announced a strategic partnership with AliveCor to provide cardiologist‑reviewed ECG interpretation services through the Kardia platform for Canadian patients.
  • The service integrates WELL’s network of Canadian‑registered cardiologists into AliveCor’s AI‑powered app, delivering clinician reviews within 24 hours and generating new clinical services revenue for WELL.
  • The partnership is positioned as the first phase, with future expansion possibilities including deployment of AliveCor’s Kardia 12L 12‑lead ECG system across WELL’s clinic network.

Key Details

  • Partnership Scope: Canadian‑registered cardiologists from WELL will review ECGs recorded on AliveCor’s Kardia devices; results are returned to patients within 24 hours.
  • Revenue Model: WELL is compensated per cardiologist review performed, creating a scalable clinical services revenue stream.
  • Clinical Benefit: Combines AI‑based arrhythmia detection (three common arrhythmias) with physician validation, aiming to reduce wait times for specialist cardiology appointments (average 15.3 weeks).
  • Future Phases: Potential rollout of AliveCor’s Kardia 12L pocket‑sized 12‑lead ECG system in WELL’s primary care, urgent care, and outpatient settings.
  • Market Context: Canadian elective cardiology wait times increased by 53 % over the past year, highlighting demand for rapid remote cardiac assessment.
  • Quotes:
  • Dina Sergi, CEO of WELL Health Diagnostic Centres: “This partnership … creates a new, scalable clinical services revenue stream for WELL.”
  • Navneet Malpani, SVP of Partner Alliances at AliveCor: “We are providing our Canadian customers with an essential layer of clinical oversight… without having to wait for in‑person appointments.”

Notable Quotes

  • “By providing clinician review to AliveCor’s AI‑driven analysis, we are helping patients get answers faster, reducing pressure on the healthcare system, and creating a new, scalable clinical services revenue stream for WELL.” – Dina Sergi, CEO, WELL Health Diagnostic Centres
  • “Patients can receive expert guidance from a certified cardiologist when they need it most, without having to wait for in‑person appointments.” – Navneet Malpani, Senior Vice President of Partner Alliances, AliveCor
Read the original news release →

More from WELL HEALTH TECHNOLOGIES CORP. J